Lipoprotein(a) and SARS-CoV-2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events.
Silvia Di Maio,Claudia Lamina,Stefan Coassin,Lukas Forer,Reinhard Würzner,Sebastian Schönherr,Florian Kronenberg +6 more
Reads0
Chats0
TLDR
In this article, the authors evaluated whether SARS-CoV-2 infections modify the risk of high lipoprotein(a) concentrations for IHD or thromboembolic events during the first 8.5 months follow-up of the pandemic.Abstract:
Background Comorbidities including ischemic heart disease (IHD) worsen outcomes after SARS-CoV-2 infections. High lipoprotein(a) [Lp(a)] concentrations are a strong risk factor for IHD and possibly for thromboembolic events. We therefore evaluated whether SARS-CoV-2 infections modify the risk of high Lp(a) concentrations for IHD or thromboembolic events during the first 8.5 months follow-up of the pandemic. Method Cohort study using data from the UK Biobank during the SARS-CoV-2 pandemic. Baseline Lp(a) was compared between SARS-CoV-2 positive patients and the population controls. UK Biobank received ethical approval from the North West Multi-Centre Research Ethics Committee (REC reference: 11/NW/0382). All participants gave written informed consent before enrolment in the study, which was conducted in accordance with the principles of the Declaration of Helsinki. Results SARS-CoV-2 positive patients had Lp(a) concentrations similar to the population controls. The risk for IHD increased with higher Lp(a) concentrations in both, the population controls (n = 435,104) and SARS-CoV-2 positive patients (n = 6,937). The causality of the findings was supported by a genetic risk score for Lp(a). A SARS-CoV-2 infection modified the association with a steeper increase in risk for infected patients (interaction P-value = 0.03). Although SARS-CoV-2 positive patients had a 5-times higher frequency of thromboembolic events compared to the population controls (1.53% vs. 0.31%), the risk was not influenced by Lp(a). Conclusions SARS-CoV-2 infections enforce the association between high Lp(a) and IHD but the risk for thromboembolic events is not influenced by Lp(a). This article is protected by copyright. All rights reserved.read more
Citations
More filters
Journal ArticleDOI
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Florian Kronenberg,Samia Mora,Erik S.G. Stroes,Brian A. Ference,Benoit J. Arsenault,Lars Berglund,Marc R. Dweck,Marlys L. Koschinsky,Gilles Lambert,François Mach,Catherine J. McNeal,Patrick M. Moriarty,Pradeep Natarajan,Børge G. Nordestgaard,Klaus G. Parhofer,Salim S. Virani,Arnold von Eckardstein,Gerald F. Watts,Jane K Stock,Kausik K. Ray,Lâle Tokgözoğlu,Alberico L. Catapano +21 more
TL;DR: Evidence for Lp(a) as a causal risk factor for cardiovascular outcomes is reinforced, and clinical guidance for testing and treating elevated Lp (a) levels is provided, and its inclusion in global risk estimation is considered.
Journal ArticleDOI
Prognostic parameters of in-hospital mortality in COVID-19 patients-An Italian experience.
Massimiliano Ruscica,Chiara Macchi,Simona Iodice,Gregorio Tersalvi,Irene Rota,Simone Ghidini,Leonardo Terranova,Luca Valenti,Luca Valenti,Francesco Amati,Stefano Aliberti,Stefano Aliberti,Alberto Corsini,Francesco Blasi,Francesco Blasi,Stefano Carugo,Stefano Carugo,Valentina Bollati,Marco Vicenzi,Marco Vicenzi +19 more
TL;DR: In this paper, the authors used multivariate Cox regression analysis to test a large spectrum of variables ranging from clinical evaluation to laboratory biomarkers to identify which parameter would best predict all-cause in-hospital mortality in COVID-19 patients.
Journal ArticleDOI
Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study
TL;DR: In this article , the authors investigated whether Lp(a) elevation may contribute to the pro-thrombotic state hallmarking COVID-19 patients, which is mainly driven by interleukin (IL)-6.
Journal ArticleDOI
Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.
TL;DR: In this paper , the authors show that elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a causal risk factor for the development of atherothrombotic disorders including coronary heart disease.
Journal ArticleDOI
Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue
Zhonglei Wang,Liyan Yang +1 more
TL;DR: The clinical sequelae of COVID-19 survivors are reviewed and valuable insights required to fill the gaps in medical knowledge are provided.
References
More filters
Journal ArticleDOI
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.
Maximilian Ackermann,Stijn E. Verleden,Mark Kuehnel,Axel Haverich,Tobias Welte,Florian Laenger,Arno Vanstapel,Christopher Werlein,Helge Stark,Alexandar Tzankov,William W. Li,Vincent W. Li,Steven J. Mentzer,Danny Jonigk +13 more
TL;DR: In this small series, vascular angiogenesis distinguished the pulmonary pathobiology of Covid-19 from that of equally severe influenza virus infection.
Journal ArticleDOI
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.
Annemarie B Docherty,Ewen M Harrison,Christopher A Green,Hayley E Hardwick,Riinu Pius,Lisa Norman,Karl A Holden,Jonathan M. Read,Frank Dondelinger,Gail Carson,Laura Merson,James A. Lee,Daniel Plotkin,Louise Sigfrid,Sophie Halpin,Clare Jackson,Carrol Gamble,Peter Horby,Jonathan S. Nguyen-Van-Tam,Antonia Ho,Clark D Russell,Jake Dunning,Jake Dunning,Peter J. M. Openshaw,J Kenneth Baillie,Malcolm G Semple +25 more
TL;DR: In study participants, mortality was high, independent risk factors were increasing age, male sex, and chronic comorbidity, including obesity, and the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks is shown.
Journal ArticleDOI
Lipoprotein(a): resurrected by genetics.
Florian Kronenberg,Gerd Utermann +1 more
TL;DR: It has been established in a proof of principle study that lowering of very high Lp(a) by apheresis in high‐risk patients with already maximally reduced low‐density lipoprotein cholesterol levels can dramatically reduce major coronary events.
Journal ArticleDOI
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
TL;DR: Human epidemiologic and genetic evidence using the Mendelian randomization approach in large-scale studies now strongly supports that elevated lipoprotein (a) [Lp(a)] is a causal risk factor for cardiovascular disease, that is, for myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis.
Journal ArticleDOI
Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.
Gregory Piazza,Umberto Campia,Shelley Hurwitz,Julia E. Snyder,Samantha Rizzo,Mariana Pfeferman,Ruth B. Morrison,Orly Leiva,John Fanikos,Victor Nauffal,Zaid Almarzooq,Samuel Z. Goldhaber +11 more
TL;DR: Major arterial or venous thromboembolism, major cardiovascular adverse events, and symptomatic venousThromboEmbolism occurred with high frequency in patients with COVID-19, especially in the intensive care setting, despite a high utilization rate of thromboprophylaxis.